Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study
Authors' conclusion
Treatment with tocilizumab/sarilumab, abatacept or rituximab in RA patients was not associated with increased risks of cancer compared with TNFi-treated and with bDMARD-naïve RA patients in a real-world setting.
Study context
- Population
- RA patients in the Danish Rheumatology Quality Register (DANBIO), followed for cancer 2006–202021,982 treatment initiations
- Exposure
- Tocilizumab/sarilumab, abatacept or rituximab vs TNF inhibitors (TNFi) and vs bDMARD-naïve
- Outcome
- Cancer (overall)
Methodological detailsinverse probability of treatment weighting, weighted cause-specific Cox models, 'latest type of treatment' allocation
- Inverse probability of treatment weighting
- Weighted cause-specific Cox models
- 'latest type of treatment' allocation
Main finding
As reported in the abstract
Overall cancer
- No statistically significant increased hazard ratios (HRs) for overall cancer in tocilizumab/sarilumab, abatacept or rituximab groups (HRs ranged from 0.7 to 1.1)
- 96 475 person years; 1423 cancers
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Overall cancer, >5 years of abatacept exposureAbataceptvs TNFi | 1.41 (0.74–2.71) | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | HR (95% CI) |
|---|---|
| Haematological cancersRituximab vs TNFi | 0.09 (0.00–2.06) |
| Haematological cancersRituximab vs bDMARD-naïve | 0.13 (0.00–1.89) |
Original publication
Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study. Rheumatology (Oxford). Published 7 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →